NUT Carcinoma Clinical Trials

6 recruitingLast updated: June 17, 2026

There are 6 actively recruiting nut carcinoma clinical trials across 2 countries. Studies span Phase 1, Phase 2. Top locations include Boston, Massachusetts, United States, Houston, Texas, United States, Pittsburgh, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


NUT Carcinoma Trials at a Glance

6 actively recruiting trials for nut carcinoma are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Boston, Houston, and Pittsburgh. Lead sponsors running nut carcinoma studies include National Cancer Institute (NCI), Azienda Ospedaliera di Padova, and Dana-Farber Cancer Institute.

Browse nut carcinoma trials by phase

Treatments under study

About NUT Carcinoma Clinical Trials

Looking for clinical trials for NUT Carcinoma? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new NUT Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about NUT Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+5 more
National Cancer Institute (NCI)45 enrolled7 locationsNCT05372640
Recruiting
Phase 1Phase 2

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Metastatic NUT CarcinomaUnresectable NUT CarcinomaAdvanced NUT Carcinoma
National Cancer Institute (NCI)36 enrolled5 locationsNCT05019716
Recruiting

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

Non-small Cell Lung CancerSmall Cell Lung CarcinomaNUT Carcinoma
Dana-Farber Cancer Institute500 enrolled4 locationsNCT05265429
Recruiting
Phase 2

Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma

Metastatic NUT CarcinomaUnresectable NUT Carcinoma
Northwestern University15 enrolled1 locationNCT07050186
Recruiting

An International Study on Pediatric Patients With Rare Tumors.

MesotheliomaThyroid CarcinomaPleuropulmonary Blastoma+11 more
Azienda Ospedaliera di Padova6,250 enrolled1 locationNCT07072143
Recruiting
Phase 1

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Castrate Resistant Prostate CancerNUT CarcinomaChronic Myelomonocytic Leukemia+1 more
Epigenetix, Inc.75 enrolled6 locationsNCT05488548